Antares Pharma announced that the FDA has approved Otrexup (methotrexate) injection, the first subcutaneous (SC) methotrexate for once-weekly self-administration with a single-dose, disposable ...
Antares Announces Podium Presentation of Pivotal OTREXUP™ (methotrexate) Data at American College of
EWING, N.J.--(BUSINESS WIRE)-- Antares Pharma, Inc. (NAS: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, ...
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...
The US Food and Drug Administration (FDA) has approved a subcutaneous injectable methotrexate delivered in an auto-injector (Rasuvo, Medac Pharma) for rheumatoid arthritis (RA), polyarticular-course ...
FDA to Review MPI-2505 NDA for RA, Psoriasis Medac Pharma announced that the FDA has approved Rasuvo (methotrexate) subcutaneous auto-injector for the management of rheumatoid arthritis, polyarticular ...
TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...
A new self-administered methotrexate autoinjector had 90.5% subject usability, according to recently published data. Christophe Hudry, MD, of the rheumatology department at Cochin Hospital in Paris, ...
TORONTO--(BUSINESS WIRE)--NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet ® for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results